FDA approves acetaminophen-naproxen sodium combination tablet for ages 12 and older

The FDA has approved the first nonprescription fixed-dose combination of acetaminophen and naproxen sodium, giving clinicians and patients aged 12 years and older a new opioid-free option for temporary relief of minor aches and pains lasting up to 12 hours.¹ The product, marketed as Tylenol with Naproxen, pairs 325 mg of acetaminophen with 110 mg of naproxen sodium per tablet; the labeled adult dose of 2 tablets delivers 650 mg of acetaminophen and 220 mg of naproxen sodium, dosed every 12 hours.¹,²

"This milestone reflects the long-standing leadership of Tylenol in translating rigorous clinical science into accessible, over-the-counter solutions," said Rajesh Mishra, MD, PhD, chief medical officer of Kenvue, the product's manufacturer, in a company statement.² Mishra added that the combination is designed to spare patients from having to time or stack 2 separate analgesics on their own.²

Regulatory basis and dosing for the acetaminophen-naproxen sodium combination

FDA's approval was supported by evidence establishing the effectiveness and safety of the combined product and demonstrating that each active ingredient contributes to the overall analgesic effect, consistent with the agency's standard for fixed-dose combination analgesics.¹ Kenvue has stated that the application was backed by 8 clinical studies showing the combination outperformed either acetaminophen or naproxen sodium alone, though full trial data have not yet been published in a peer-reviewed journal and are expected to be presented at PAINWeek 2026.² The labeling mirrors existing acetaminophen- and NSAID-containing OTC products, and FDA has granted the formulation 3 years of marketing exclusivity.¹,²

Clinical context: an expanding nonopioid analgesic category

Acetaminophen and naproxen sodium are each among the most widely used OTC analgesics in the United States, with decades of independent safety data, but until now no product combined them in one tablet.¹ Acetaminophen/NSAID combinations have shown additive or synergistic analgesic effects in prior pain models, including postoperative and headache studies, on the rationale that the 2 drug classes act through distinct mechanisms.³ A separate industry-sponsored trial in adolescents aged 12 to younger than 17 years evaluated multiple-dose safety of an acetaminophen/naproxen sodium fixed combination for pain, reflecting the extension of this drug class to the adolescent population now included in the approved indication.⁴

Safety considerations clinicians should reinforce

The labeling carries the standard warnings for both ingredient classes: a liver-injury warning against combining the product with other acetaminophen-containing medications, and NSAID-related warnings for gastrointestinal bleeding and increased risk of heart attack, heart failure, and stroke, risks FDA notes are heightened with use beyond directed dose or duration.¹ As with other NSAID-containing OTC products, the label advises that naproxen sodium not be used at 20 weeks of pregnancy or later unless specifically directed by a physician, and that pregnant or breastfeeding patients consult a health professional before use.¹

Interpreting the approval and open questions

FDA's action arrives alongside a broader administration initiative to shift more prescription-tier pharmaceuticals to OTC status, an effort the agency's announcement explicitly linked to reducing costs and expanding access.¹ For clinicians, the approval formalizes a combination that some patients likely already improvised by taking acetaminophen and naproxen sodium separately, but with a fixed 3:1 ratio and defined dosing interval rather than individualized titration. Because the supporting clinical program has not been published in full, the durability of the reported efficacy advantage, its performance against other established combinations such as acetaminophen-ibuprofen, and safety in adolescents specifically over repeated dosing cycles remain to be independently assessed.³,⁴

3 Takeaways

• Tylenol with Naproxen (acetaminophen 325 mg/naproxen sodium 110 mg per tablet) is the first FDA-approved OTC fixed-dose combination of these 2 agents, labeled for ages 12 and older with dosing every 12 hours.
• Counsel patients on the same NSAID and acetaminophen precautions that apply to the individual ingredients: liver injury risk with overlapping acetaminophen sources, GI bleeding, cardiovascular risk, and pregnancy restrictions after 20 weeks.
• The manufacturer's efficacy claims rest on 8 clinical studies not yet published in the peer-reviewed literature; clinicians should watch for that data, expected at PAINWeek 2026, before drawing firm comparative conclusions.

References

1. US Food and Drug Administration. FDA approves first nonprescription fixed-dose combination of acetaminophen and naproxen sodium for 12-hour pain relief. Published July 24, 2026. Accessed July 24, 2026. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-nonprescription-fixed-dose-combination-acetaminophen-and-naproxen-sodium-12-hour

2. Kenvue Inc. FDA approves Tylenol with Naproxen, the first and only over-the-counter fixed-dose combination of acetaminophen (650 mg) and naproxen sodium (220 mg). Published July 24, 2026. Accessed July 24, 2026. https://www.prnewswire.com/news-releases/fda-approves-tylenol-with-naproxen-the-first-and-only-over-the-counter-fixed-dose-combination-of-acetaminophen-650-mg-and-naproxen-sodium-220-mg-302834313.html

3. Altman RD, Zinsenheim JR. A rationale for combining acetaminophen and NSAIDs for mild-to-moderate pain. Clin Exp Rheumatol. Accessed July 24, 2026. https://www.clinexprheumatol.org/article.asp?a=2284

4. ClinicalTrials.gov. A study of acetaminophen/naproxen sodium fixed combination tablets in adolescents 12 to <17 years of age with pain. Identifier NCT05844995. Accessed July 24, 2026. https://clinicaltrials.gov/study/NCT05844995